rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Critical Gap: GLP-1/GIP Drug Trials Don't Adequately Report Dietary Changes

RPEP-153702026Jansson, Anna K; Gómez-Martín, María; Hedin, Linnea; Clarke, Erin D; Cross, Victoria; Stanford, Jordan; Taylor, Rachael M; Bogl, Leonie H; De Vlieger, Nienke; Koochek, Afsaneh; Löf, Marie; Asher, Roberta C; Burrows, Tracy; Bucher, Tamara; Sullivan, Clair; Nowicka, Paulina; Collins, Clare E
evidence
The takeaway

Systematic review finds critical evidence gaps in how RCTs of GLP-1/GIP drugs report dietary intake changes, limiting understanding of how these drugs affect eating behavior and nutritional status.

What do they eat?

GLP-1 drugs suppress appetite dramatically, but trials rarely report what dietary changes occur — a critical knowledge gap for patient management

What the researchers found

Systematic review reveals critical evidence gaps in RCT reporting of dietary intake and quality changes during GLP-1/GIP therapy, limiting nutritional management guidance.

Why it matters

Patients on GLP-1 drugs eat significantly less. Without knowing WHAT they eat less of, nutritional deficiencies may go undetected.

How the study worked

Systematic review of RCTs assessing dietary change reporting during GLP-1/GIP RA treatment.

What this study cannot tell us

Cannot assess what isn't reported. Review of trial reporting practices, not clinical outcomes.

How to read the evidence

Systematic review of reporting quality. Important meta-research finding.

When this study was published

Published in 2025.

The bigger picture

As GLP-1 drugs become lifelong therapies for millions, understanding and managing their effects on nutrition is essential for overall health.

Questions still open

  • Should all GLP-1 drug users receive dietary counseling?
  • Do patients on GLP-1 drugs develop specific nutrient deficiencies?
  • Should future trials include mandatory dietary assessment?

Common questions

Do GLP-1 drugs cause nutritional problems?
We don't know well enough — this review found most drug trials don't adequately measure what dietary changes occur. Since these drugs strongly reduce appetite, nutritional monitoring is important.
Should I take vitamins on GLP-1 drugs?
Given the appetite reduction, a multivitamin and adequate protein intake are reasonable precautions. Discuss specific nutritional needs with your doctor or dietitian.

Read the original research

A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.

Obesity reviews : an official journal of the International Association for the Study of Obesity, e70077

View on PubMed ↗Publisher’s paper ↗

Citation

Jansson, Anna K; Gómez-Martín, María; Hedin, Linnea; Clarke, Erin D; Cross, Victoria; Stanford, Jordan; Taylor, Rachael M; Bogl, Leonie H; De Vlieger, Nienke; Koochek, Afsaneh; Löf, Marie; Asher, Roberta C; Burrows, Tracy; Bucher, Tamara; Sullivan, Clair; Nowicka, Paulina; Collins, Clare E. (2026). A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.. Obesity reviews : an official journal of the International Association for the Study of Obesity, e70077. https://doi.org/10.1111/obr.70077